Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study

Deborah J. Engen, Samantha J. McAllister, Mary O. Whipple, Stephen S. Cha, Liza J. Dion, Ann Vincent, Brent A Bauer, Dietlind L. Wahner-Roedler

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: Fibromyalgia is a syndrome characterized by chronic pain, fatigue, depression, and sleep disturbances. Its primary cause is unclear. Several studies have reported decreased intracellular magnesium levels in patients with fibromyalgia and have found negative correlation between magnesium levels and fibromyalgia symptoms.

OBJECTIVE: To gather preliminary data on whether transdermal magnesium can improve quality of life for women who have fibromyalgia.

DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a patient questionnaires and survey in a fibromyalgia clinic at a tertiary medical center. Forty female patients with the diagnosis of fibromyalgia were enrolled. Each participant was provided a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per limb twice daily for 4 weeks. Participants were asked to complete the Revised Fibromyalgia Impact Questionnaire, SF-36v2 Health Survey, and a quality-of-life analog scale at baseline, week 2, and week 4.

MAIN OUTCOME MEASURE: Questionnaire and survey scores, evaluated through intent-to-treat and per-protocol analyses.

RESULTS: Twenty-four patients completed the study (mean [SD] age, 57.2 [7.6] years; white, 95%; mean body mass index, 31.3 kg/m2). With intention-to-treat analysis, Revised Fibromyalgia Impact Questionnaire subscale and total scores were significantly improved at week 2 and week 4 (total score, P=0.001). Per-protocol analysis results were similar: all subscales of the Revised Fibromyalgia Impact Questionnaire were significantly improved at week 2 and week 4 (total score, P=0.001).

CONCLUSION: This pilot study suggests that transdermal magnesium chloride applied on upper and lower limbs may be beneficial to patients with fibromyalgia.

TRIAL REGISTRATION: ClinicalTrials.gov.ldentifier NCT01968772.

Original languageEnglish (US)
Pages (from-to)306-313
Number of pages8
JournalJournal of integrative medicine
Volume13
Issue number5
DOIs
StatePublished - Sep 1 2015

Fingerprint

Magnesium Chloride
Fibromyalgia
Feasibility Studies
Quality of Life
Magnesium
Intention to Treat Analysis
Health Surveys
Chronic Pain
Fatigue
Lower Extremity
Sleep
Body Mass Index
Extremities
Surveys and Questionnaires
Depression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Engen, D. J., McAllister, S. J., Whipple, M. O., Cha, S. S., Dion, L. J., Vincent, A., ... Wahner-Roedler, D. L. (2015). Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study. Journal of integrative medicine, 13(5), 306-313. https://doi.org/10.1016/S2095-4964(15)60195-9

Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia : a feasibility study. / Engen, Deborah J.; McAllister, Samantha J.; Whipple, Mary O.; Cha, Stephen S.; Dion, Liza J.; Vincent, Ann; Bauer, Brent A; Wahner-Roedler, Dietlind L.

In: Journal of integrative medicine, Vol. 13, No. 5, 01.09.2015, p. 306-313.

Research output: Contribution to journalArticle

Engen, Deborah J. ; McAllister, Samantha J. ; Whipple, Mary O. ; Cha, Stephen S. ; Dion, Liza J. ; Vincent, Ann ; Bauer, Brent A ; Wahner-Roedler, Dietlind L. / Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia : a feasibility study. In: Journal of integrative medicine. 2015 ; Vol. 13, No. 5. pp. 306-313.
@article{6789cede96624dddabad9a2d935f4bdb,
title = "Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study",
abstract = "BACKGROUND: Fibromyalgia is a syndrome characterized by chronic pain, fatigue, depression, and sleep disturbances. Its primary cause is unclear. Several studies have reported decreased intracellular magnesium levels in patients with fibromyalgia and have found negative correlation between magnesium levels and fibromyalgia symptoms.OBJECTIVE: To gather preliminary data on whether transdermal magnesium can improve quality of life for women who have fibromyalgia.DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a patient questionnaires and survey in a fibromyalgia clinic at a tertiary medical center. Forty female patients with the diagnosis of fibromyalgia were enrolled. Each participant was provided a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per limb twice daily for 4 weeks. Participants were asked to complete the Revised Fibromyalgia Impact Questionnaire, SF-36v2 Health Survey, and a quality-of-life analog scale at baseline, week 2, and week 4.MAIN OUTCOME MEASURE: Questionnaire and survey scores, evaluated through intent-to-treat and per-protocol analyses.RESULTS: Twenty-four patients completed the study (mean [SD] age, 57.2 [7.6] years; white, 95{\%}; mean body mass index, 31.3 kg/m2). With intention-to-treat analysis, Revised Fibromyalgia Impact Questionnaire subscale and total scores were significantly improved at week 2 and week 4 (total score, P=0.001). Per-protocol analysis results were similar: all subscales of the Revised Fibromyalgia Impact Questionnaire were significantly improved at week 2 and week 4 (total score, P=0.001).CONCLUSION: This pilot study suggests that transdermal magnesium chloride applied on upper and lower limbs may be beneficial to patients with fibromyalgia.TRIAL REGISTRATION: ClinicalTrials.gov.ldentifier NCT01968772.",
author = "Engen, {Deborah J.} and McAllister, {Samantha J.} and Whipple, {Mary O.} and Cha, {Stephen S.} and Dion, {Liza J.} and Ann Vincent and Bauer, {Brent A} and Wahner-Roedler, {Dietlind L.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/S2095-4964(15)60195-9",
language = "English (US)",
volume = "13",
pages = "306--313",
journal = "Journal of integrative medicine",
issn = "2095-4964",
publisher = "Science Press (China)",
number = "5",

}

TY - JOUR

T1 - Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia

T2 - a feasibility study

AU - Engen, Deborah J.

AU - McAllister, Samantha J.

AU - Whipple, Mary O.

AU - Cha, Stephen S.

AU - Dion, Liza J.

AU - Vincent, Ann

AU - Bauer, Brent A

AU - Wahner-Roedler, Dietlind L.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - BACKGROUND: Fibromyalgia is a syndrome characterized by chronic pain, fatigue, depression, and sleep disturbances. Its primary cause is unclear. Several studies have reported decreased intracellular magnesium levels in patients with fibromyalgia and have found negative correlation between magnesium levels and fibromyalgia symptoms.OBJECTIVE: To gather preliminary data on whether transdermal magnesium can improve quality of life for women who have fibromyalgia.DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a patient questionnaires and survey in a fibromyalgia clinic at a tertiary medical center. Forty female patients with the diagnosis of fibromyalgia were enrolled. Each participant was provided a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per limb twice daily for 4 weeks. Participants were asked to complete the Revised Fibromyalgia Impact Questionnaire, SF-36v2 Health Survey, and a quality-of-life analog scale at baseline, week 2, and week 4.MAIN OUTCOME MEASURE: Questionnaire and survey scores, evaluated through intent-to-treat and per-protocol analyses.RESULTS: Twenty-four patients completed the study (mean [SD] age, 57.2 [7.6] years; white, 95%; mean body mass index, 31.3 kg/m2). With intention-to-treat analysis, Revised Fibromyalgia Impact Questionnaire subscale and total scores were significantly improved at week 2 and week 4 (total score, P=0.001). Per-protocol analysis results were similar: all subscales of the Revised Fibromyalgia Impact Questionnaire were significantly improved at week 2 and week 4 (total score, P=0.001).CONCLUSION: This pilot study suggests that transdermal magnesium chloride applied on upper and lower limbs may be beneficial to patients with fibromyalgia.TRIAL REGISTRATION: ClinicalTrials.gov.ldentifier NCT01968772.

AB - BACKGROUND: Fibromyalgia is a syndrome characterized by chronic pain, fatigue, depression, and sleep disturbances. Its primary cause is unclear. Several studies have reported decreased intracellular magnesium levels in patients with fibromyalgia and have found negative correlation between magnesium levels and fibromyalgia symptoms.OBJECTIVE: To gather preliminary data on whether transdermal magnesium can improve quality of life for women who have fibromyalgia.DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a patient questionnaires and survey in a fibromyalgia clinic at a tertiary medical center. Forty female patients with the diagnosis of fibromyalgia were enrolled. Each participant was provided a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per limb twice daily for 4 weeks. Participants were asked to complete the Revised Fibromyalgia Impact Questionnaire, SF-36v2 Health Survey, and a quality-of-life analog scale at baseline, week 2, and week 4.MAIN OUTCOME MEASURE: Questionnaire and survey scores, evaluated through intent-to-treat and per-protocol analyses.RESULTS: Twenty-four patients completed the study (mean [SD] age, 57.2 [7.6] years; white, 95%; mean body mass index, 31.3 kg/m2). With intention-to-treat analysis, Revised Fibromyalgia Impact Questionnaire subscale and total scores were significantly improved at week 2 and week 4 (total score, P=0.001). Per-protocol analysis results were similar: all subscales of the Revised Fibromyalgia Impact Questionnaire were significantly improved at week 2 and week 4 (total score, P=0.001).CONCLUSION: This pilot study suggests that transdermal magnesium chloride applied on upper and lower limbs may be beneficial to patients with fibromyalgia.TRIAL REGISTRATION: ClinicalTrials.gov.ldentifier NCT01968772.

UR - http://www.scopus.com/inward/record.url?scp=85050580267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050580267&partnerID=8YFLogxK

U2 - 10.1016/S2095-4964(15)60195-9

DO - 10.1016/S2095-4964(15)60195-9

M3 - Article

C2 - 26343101

AN - SCOPUS:85050580267

VL - 13

SP - 306

EP - 313

JO - Journal of integrative medicine

JF - Journal of integrative medicine

SN - 2095-4964

IS - 5

ER -